PATENT COOPERATION TREATY CIO: 262

INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

To: F B Rice & Co 605 Darling Street BALNIAIN NSW 2041 Applicants or agent's file reference 115565/BAL International Application No. RECEIVED A FEB 2004 F. B. PHCE & CO. International Filing Dargenty Control of the Control	PCT WRITTEN OPINION (PCT Rule 66) Date of mailing 2 3 FEB 2004 (day/month/year) REPLY DUE within TWO MONTHS from the shove date of mailing					
PCT/AU2803/601912 11 August 2003	/month/year) Priority Date (day/month/year) 9 August 2002					
International Patent Classification (IPC) or both national classification and IPC						
Int. Cl. A61F 11/00, A61B 17/56						
Applicant						
COCHLEAR LIMITED et al						
1. This written opinion is the first drawn by this Internation						
2. This opinion contains indications relating to the following iter	nst,					
1 X Basis of the opinion						
II Priority	Priority					
III Non-establishment of opinion with regard to nevelty, in	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability					
IV Lack of unity of invention	ack of unity of invention					
V K Reasoned statement under Rule 66.2(a)(ii) with regard to explanations supporting such statement	Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement					
VI Certain documents cited						
VII Certain defects in the international application	Certain defects in the international application					
VIII Certain observations on the international application	Certain observations on the international application					
3. The FINAL DATE by which the international preliminary examination report must be established according to Rule 69.2 is: 9 December 2004						
4. The applicant is hereby invited to reply to this opinion.						
Witen? See the Reply Due date indicated above. However, the Australian Patent Office will not establish the Report before the earlier of (i) a response being filed, or (ii) one month before the Final Date by which the international preliminary examination report must be established. The Report will take into account any response (including amendments) filed before the Report is established. If no response is filed by 1 month before the Final Date, the international preliminary examination report will be established on the basis of this opinion. Applicants wishing to have the benefit of a further opinion (if needed) before the report is established should ensure that a response is filed at least 3 months before the Final Date by which the international preliminary examination report must be established.						
How? By submitting a written reply, accompanied, where appro- For the form and the language of the amendments, see Ru	How? By submitting a written reply, accompanied, where appropriate, by amendments, according to Rule 66.3. For the form and the language of the amendments, see Rules 66.8 and 66.9.					
Also For an additional opportunity to submit amendments, see Rule 66.4. For the examiner's obligation to consider amendments and/or arguments, see Rule 66.4bis. For an informal communication with the examiner, see Rule 66.6.						
Name and mading address of the IPEA/AU	Authorized Officer					
AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA						
E-mail address: poi@ipeustralia gov.au SUE THOMAS Facsimile No. (02) 6285-3939						
	Telephone No. (62) 6283-2454					

some of the second some some some some

WRITTEN OPINION

International application No.

PCT/AU2003/001012

3.	Basis of the op	inion					
1.	With regard to the e	n regard to the elements of the international application:*					
	ine internation	the international application as originally filed.					
	the description	n, pages, as originally filed,					
		pages , filed with the demand,					
		pages, received on with the letter of					
	the claims,	pages , as originally filed,					
		pages , as amended under Article 19,					
		pages , filed with the demand,					
	v	pages , received on with the letter of					
	the drawings,	pages , as originally filed.					
		pages , filed with the demand.					
		pages, received on with the letter of					
	the sequence	listing part of the description:					
		pages , as originally filed					
		pages , filed with the demand					
		pages, received on with the letter of					
2.	which the internation These elements were the language the language the language	anguage, all the elements marked above were available or furnished to this Authority in the language in mal application was filed, unless otherwise indicated under this item. The available or furnished to this Authority in the following language—which is: of a translation furnished for the purposes of international search (under Rule 23:1(b)). of publication of the international application (under Rule 48.3(b)). of the translation furnished for the purposes of international preliminary examination (under Rules 55.2					
3.	With regard to any	and/or 55.3). Fith regard to any nucleotide and/or amino acid sequence disclosed in the international application, the written opinion was					
	protect	of the sequence listing:					
	accord	contained in the international application in printed form.					
		filed together with the international application in computer readable form.					
furnished subsequently to this Authority in written form. furnished subsequently to this Authority in computer readable form. The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the							
	furnished sul	sequently to this Authority in computer readable form.					
-	11355111241131183	at that the subsequently furnished written sequence listing does not go beyond the disclosure in the application as filed has been furnished.					
	The statement been furnished	it that the information recorded in computer readable form is identical to the written sequence listing bas- ed.					
4.	The amendre	sents have resulted in the cancellation of:					
	[] the	description, pages					
	the	claims, Nos.					
	the	claims, Nos. drawings, sheets/fig.					
5.	This opinion	has been established as if (some of) the amendments had not been made, since they have been considered to see disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).					
* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this opinion as "originally filed"							

WRITTEN OPINION

International application No.

PCT/AU2003/001012

Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability;
 citations and explanations supporting such statement

1. Sistement

Novelty (N)	Claims	16-19, 21, 26, 32-42	YES
W. Company	Claims	1-15, 20, 22-25, 27-31	NO
Inventive step (1S)	Claims	16-19, 21, 36-40, 42	YES
*	Claims	1-15, 20, 22-35, 41	NO
Industrial applicability (IA)	Claims	1-42	YES
ř	Claims	•	NO

2. Chations and explanations

The following documents identified in the International Search Report have been considered for the purposes of this report:

D1....US 6,427,086

D2....US 6,132,384

Novelty (N) Claims 1-15, 20, 22-25, 27-31

Claims 1-10, 12-15, 20, 22-25, 27-31: D) discloses a neurostimulator (620) implantable into cavity in the cranium; the upper surface of the implant having a flange member (622) extending outwardly beyond the outward extent of the lower surface of the housing, the flange member adapted to abut the surface of the bone surrounding the cavity (column 35 lines 1 to 4).

Similarly D2 discloses the features of claims 1-5, 13, 14

Claim 11: D2 discloses a flange (158) which is an integral extension of the implant.

Inventive Step (IS) Claims 1-15, 20, 22-35, 41

Claims 1-15, 20, 22-25, 27-31 lack novelty and consequently lack inventive step.

Claims 26: Although D1 does not disclose the feature of making the flange integral with the faceplate, this would be considered obvious to a PSA and consequently lacks inventive step.

Claim 32-35: Although D1 does not disclose the feature of making the faceplate separately from the housing, this would be considered obvious to a PSA and consequently lacks inventive step.

Claim 41: Although D1 does not disclose all the steps of the method claimed, they would be considered obvious to a PSA and consequently lack inventive step.